Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

100.40 -1.44 (-1.41%)
Official Closing Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?
Lilly's Mounjaro is gaining ground on Novo Nordisk's Ozempic. 
Via The Motley Fool
1 Stock-Split Stock to Buy Hand Over Fist in November, and 1 to Avoid
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a phenomenally cheap industry leader, as well as an exceptionally pricey company... 
Via The Motley Fool
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 5 Years
Via Benzinga
Why Novo Nordisk Stock Is Surging Higher Today
The drugmaker's type 2 diabetes and weight-loss treatment is a growth powerhouse. 
Via The Motley Fool
Earnings Preview For Novo Nordisk
Via Benzinga
Novo Nordisk (NVO) Q3 2023 Earnings Call Transcript
NVO earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Wegovy Maker Novo Nordisk's Obesity, Diabetes Drug Sales Hit Whopping $22B In Nine Months, Prepares To Expand Capacity
Novo Nordisk A/S's (NYSE: NVO) sales for Q3 FY23 climbed 29% Y/Y to DKK 
Via Benzinga
Novo Nordisk Stock Jumps As Wegovy Sales Skyrocket 734%, Crushing Expectations
The company's weight-loss drug beat expectations, though sales of diabetes shot Ozempic came in light. 
Via Investor's Business Daily
Weight Watchers Q3 Earnings Preview: Will Ozempic Weigh Down WW Stock?
Weight Watchers stock, trading as WW, is already down 30% YTD. Here's what analysts will be watching in the Q3 earnings report. 
Via Benzinga
7 A-Rated Tech Stocks to Buy for November
By investing in tech stocks, investors can capitalize on groundbreaking technological advancements and be a part of the future. 
Via InvestorPlace
'AI' Crowned 2023's Word Of The Year, Nudges Out Greedflation, Deinfluencing
AI is named the word of the year by a leading dictionary. Find out why and what other words almost beat it. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novo Nordisk Unusual Options Activity For October 30
Via Benzinga
Looking At Novo Nordisk's Recent Unusual Options Activity
Via Benzinga
Earnings Due For Stealth GLP-1 Weight-Loss Drug Play McKesson, Rivals
McKesson earnings are on tap, with Cencora and Cardinal Health due soon. 
Via Investor's Business Daily
These Foods Have An Ozempic-Like Effect And Could Help You Lose Weight
GLP-1s, or weight-loss drugs like Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy, are helping millions of Americans manage their weight and diabetes. 
Via Benzinga
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
Ozempic Supply Is Running Low: Here's Why That Can Be A Problem
Ozempic, the diabetes drug also used as a so-called "miracle" weight-loss drug, has been sweeping through America and is now in limited supply. 
Via Benzinga
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
Viatris now faces a narrower path to commercializing a generic copy of Ozempic. 
Via The Motley Fool
Can Diabetes, Weight-Loss Drugs Get Even Better?
Via Investor Brand Network
Can Diabetes, Weight-Loss Drugs Get Even Better?
EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Novo Nordisk Just Consolidated Its Grip on Yet Another Market. Is It a Buy?
Novo Nordisk is planting the seeds to become a competitor in chronic kidney disease therapies. 
Via The Motley Fool
Benzinga Bulls And Bears: Tesla, Chevron, Eli Lilly And Dogecoin Co-founder's 3 Favorite Cryptos
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Is Ozempic Killing Liposuction? A Stock That Could Get Hit Hard From New Weight-Loss Drugs
Ozempic, Novo Nordisk’s (NYSE: NVO) diabetes drug, is now popular for weight loss. The rise of the drug could become a major headwind for other companies that provide weight-loss services such... 
Via Benzinga
Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact?
Makers of devices to treat obesity-related conditions have struggled recently. Analysts say there's more to the story. 
Via Investor's Business Daily
3 Monster Buy-and-Hold Growth Stocks to Buy Right Now for $1K
These are three growth stocks you will want to buy and never sell if you have $1,000 available to invest today. 
Via InvestorPlace
Weight Loss Drugs Like Wegovy Would Not Impact Business - Healthcare Companies Tell Investors
Novo Nordisk A/S (NYSE: NVO) investors and analysts eagerly await the company's third-quarter results, hoping for clarity on when supply limitations for its weight-loss drug, Wegovy, in the U.S.  
Via Benzinga
Q3 Earnings Season Scorecard - Earnings Growth Turns Positive
The Q3 revenue beats percentage of 63.2% is the lowest since the 61.7% for this group of companies in 2020 Q1. 
Via Talk Markets
Weight Loss Drugs Wegovy, Ozempic Gain Traction With Millennials, High Earners: New Survey Results
A new survey reveals the consumer segments showing the greatest interest in weight loss medications such as Ozempic, Mounjaro, and Wegovy. 
Via Benzinga
Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027
EQNX::TICKER_START (OTCPK:CNER),(NYSE:NVO),(NASDAQ:TNDM),(NASDAQ:DXCM),(NASDAQ:LXRX) EQNX::TICKER_END 
Via FinancialNewsMedia
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.